A LANDMARK MILESTONE: Human Biome S.A. fully closes its $20M (75.5M PLN) Series A round with the final $7M tranche.

We are thrilled to announce the successful completion of our third and final investment tranche of $7M (27.51M PLN). Combined with our earlier milestones ($4M in Tranche 1 and $9M in Tranche 2), Human Biome has officially reached its ultimate Series A funding target of $20M (75.5M PLN) for this Year. This tremendous achievement reflects the strong conviction and continued partnership of our investor community.

Accelerating the future of therapeutics
With the full Series A funding secured, we are supercharging the final development of our proprietary MicroDrug platform. This includes improving a state-of-the-art genomic–culturomic laboratory dedicated to synthesizing the world’s first fully biosynthetic (donor-independent) medical microbiota engineered as a New-Generation Biotherapeutic (NGB) drug. Our first indications for the NGBs are 1) antibiotic-resistant bacteria decolonization with infection prevention and 2) healthy-ageing by lowering inflammagening, pace of ageing and improving gut-brain axis.

“We are pleased to have reached the minimum target of our Series A round. The raised financing will be dedicated to completing our innovative platform for the prediction and synthesis of biosythetic microbiomes designed to restore the full spectrum of a healthy microbiome’s functions. Reaching this milestone brings us directly closer to initiating the clinical evaluation of our medical  biotherapeutics in the areas of antibiotic-resistant bacteria, as well as healthy-ageing and longevity,” says Jarosław Biliński, MD, PhD, CEO of Human Biome S.A.

Human Biome is stepping boldly onto the world stage, poised to become a driving force in the next wave of microbiome-based healthcare solutions.

Warsaw, November 17, 2026